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Abstract: Staphylococcus aureus is a key bacterium commonly found in numerous infections. 
S. aureus infections are difficult to treat due to their biofilm formation and documented antibiotic 
resistance. While selenium has been used for a wide range of applications including anticancer 
applications, the effects of selenium nanoparticles on microorganisms remain largely unknown 
to date. The objective of this in vitro study was thus to examine the growth of S. aureus in the 
presence of selenium nanoparticles. Results of this study provided the first evidence of strongly 
inhibited growth of S. aureus in the presence of selenium nanoparticles after 3, 4, and 5 hours 
at 7.8, 15.5, and 31 µg/mL. The percentage of live bacteria also decreased in the presence of 
selenium nanoparticles. Therefore, this study suggests that selenium nanoparticles may be used 
to effectively prevent and treat S. aureus infections and thus should be further studied for such 
applications.
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Introduction
Staphylococcus aureus is a Gram-positive bacteria. S. aureus infection is one of the 
most common causes of skin infections in the US. These infections can be serious 
when they occur on surgical wounds, in the bloodstream, or in the lungs. Each year, 
there are more than 11 million outpatient/emergency room visits and 464,000 hospital 
admissions in the US due to S. aureus infections.1 S. aureus infections are complicated, 
as the bacterial strains have become increasingly resistant to many commonly 
used  antibiotics. For example, a methicillin-resistant S. aureus infection is difficult to 
treat, as it is resistant to a large group of antibiotics (beta-lactams) including oxacillin, 
penicillin, and amoxicillin. S. aureus often infects patients at hospitals due to the 
patients’ already weakened immune systems and procedures they undergo such as 
surgeries and introduction of catheters, dialysis tubes, or endotracheal tubes. For 
example, during insertion of an orthopedic implant, bacteria (among them, S. aureus 
is key) from the patient’s own skin and/or mucosa enters the wound site. Bacterial 
infection of implants is one of the leading causes of implant failure.
Even more troublesome, bacteria can easily form biofilms when they attach to a 
surface. A bacterial biofilm is an aggregate of one or more types of bacteria in a 
hydrated polymeric matrix.2 Biofilms are a common cause of persistent infections as 
they are easy to form but hard to treat. S. aureus biofilms have been found on a wide 
range of medical devices including prosthetic heart valves, central venous catheters, 
urinary catheters, orthopedic prostheses, penile prostheses, contact lenses, endocarditis, 
otitis media, osteomyelitis, and sinusitis.3 Once formed, S. aureus biofilms are even 
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more difficult to treat due to the polymeric exopolysaccharide 
matrix they synthesize. This polymeric matrix works as a 
shield to prevent drugs from penetrating inside the biofilm. 
Therefore, it is desirable to develop active molecules that 
kill S. aureus at very early stages of infection, thereby pre-
venting the formation of hard-to-treat biofilms.
Along these lines, selenium has been investigated for vari-
ous medical applications such as anticancer applications. 
Selenium as a dietary supplement has been demonstrated to 
reduce the risks of various types of cancers including prostate 
cancer,4,5 lung cancer,6 and esophageal and gastric-cardiac 
cancers.7 Selenium-enriched probiotics have been shown to 
strongly inhibit the growth of pathogenic Escherichia coli 
in vivo and in vitro.8 It was shown in that study that selenium-
enriched probiotics (at a concentration of 0.509 µg selenium 
per gram of probiotics) inhibited the growth of E. coli after 
96 hours in vitro. In vivo, mice were fed with and without 
selenium-enriched probiotics for 28 days and then inoculated 
with E. coli; mortality of the treated group was the lowest.8 
A series of organoselenium compounds (such as 2,4,6-tri-para-
methoxyphenylselenopyrylium chloride, 9-para- chloropheny
loctahydroselenoxanthene, and perhydroselenoxanthene) have 
been synthesized and shown to have antibacterial activities in 
vitro, especially against S. aureus.9–11 However, the effects of 
elemental selenium nanoparticles on microorganisms remain 
largely unknown.
Nanotechnology has enabled researchers to synthesize 
nanosized particles (that is, particles that have sizes less than 
100 nm in at least one dimension), using them in a wide range 
of applications. Nanoparticles possess increased surface areas 
and therefore have increased interactions with biological 
targets (such as bacteria) compared with conventional, 
micronparticles. In addition, nanoparticles are much more 
likely to enter cells than micron particles. As a result, nano-
antibacterial particles will likely exert stronger effects on 
bacteria than their micro-counterparts. Therefore, the objec-
tive of this study was to examine the growth of S. aureus in 
the presence of selenium nanoparticles. In doing so, this 
study revealed a new type of antibacterial selenium nanopar-
ticle capable of decreasing S. aureus growth.
Materials and methods
synthesis of selenium nanoparticles
Selenium nanoparticles were synthesized by the reduction of 
sodium selenite (Alfa Aesar, Ward Hill, MA) by glutathione 
(reduced form, GSH) (TCI America, Portland, OR) and sta-
bilized by bovine serum albumin (BSA) (Sigma-Aldrich, St 
Louis, MO). Specifically, 3 mL of 25 mM Na
2
SeO
3
, 3 mL of 
100 mM GSH, and 0.15 g BSA were added to 9 mL of double 
distilled water in a sterile cabinet. All solutions were made 
in a sterile environment by using a sterile cabinet and double 
distilled water. After mixing the reactant solution, 1 M NaOH 
was added to bring the pH of the solution to the alkaline 
regimen. Selenium nanoparticles were formed immediately 
following the addition of NaOH as visualized by a color 
change of the reactant solution from clear white to clear red. 
Selenium nanoparticles were then collected by centrifuging 
the solution at 13,000 rpm, sterilized by ultraviolet light 
exposure, and resuspended in sterile double distilled water 
five times before use in bacteria experiments.
Material characterization
The size and morphology of the selenium nanoparticles were 
investigated by using a transmission electron microscope 
(TEM). For this, the nanoparticles in deionized water were 
allowed to slowly dry on formvar-coated copper grids. 
All imaging was carried out using a Philips JOEL TEM 
(New York, NY) at a voltage of 80 kV.
The size distribution of selenium nanoparticles was fur-
ther investigated by the dynamic light scattering (DLS) 
technique using a Zetasizer-Nano-S90 (Malvern Instruments, 
Malvern, Worcestershire, UK).
Bacteria assays
S. aureus
A bacterial cell line of biofilm-producing S. aureus was 
obtained in freeze-dried form from the American Type Culture 
Collection (catalog number 25923). The cells were propagated 
in 30 mg/mL of Tryptic soy broth (TSB) (MP Biomedicals, 
Solon, OH). Once the second passage of bacteria reached its 
stationary phase, the second passage was frozen in one part 
TSB and one part 50% glycerol (Sigma-Aldrich). All experi-
ments were conducted from this frozen stock. One day before 
bacterial seeding, a sterile 10 µL loop was used to withdraw 
bacteria from the frozen stock and streaked onto a TSB agar 
plate and incubated at 37°C for 16 hours. Bacteria from a 
single colony were then collected using a sterile loop and 
inoculated in a test tube containing 3 mL of TSB overnight. 
The test tube was agitated in an incubator at 37°C and shaking 
at 250 rpm to achieve a bacteria solution at the exponential 
phase of growth. Bacteria concentration was assessed by 
measuring the optical density of the bacterial solution at 
562 nm using a standard curve correlating optical densities 
and bacterial concentrations. A bacteria solution was prepared 
at a concentration of 50,000 bacteria/mL for the bacteria 
experiments as described in the following page.
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S. aureus experiments
Three concentrations of selenium nanoparticles were tested 
against S. aureus growth: 7.8, 15.5, and 31 µg/mL. Selenium 
nanoparticles were mixed with bacterial solutions and cultured 
for 3, 4, and 5 hours in an incubator (37°C, humidified, 
5% CO
2
), shaking at 250 rpm. Bacteria cultured in TSB without 
selenium nanoparticles in an incubator (37°C, humidified, 
5% CO
2
), shaking at 250 rpm, were used as the controls. Blank 
solutions were prepared by adding selenium nanoparticles into 
TSB without bacteria at the above particle concentrations. Blank 
solutions of TSB without bacteria and without selenium nano-
particles were used as the blank for controls. At the end of the 
prescribed time period, bacteria concentrations in the solution 
were determined by measuring the optical density that was then 
converted to bacteria concentrations using the standard curve 
described above. For this, 200 µL of bacteria solutions, controls, 
or blanks were added to the wells of a 96-well plate, and optical 
densities were measured at 562 nm using a  SpectraMax M5 
plate reader (Molecular Devices, Sunnyvale, CA). The mea-
sured optical densities of bacterial solutions were subtracted 
by that of the corresponding blanks.
Live/dead assays
At the end of the prescribed time period, live/dead assays were 
conducted using a BacLight Bacterial Viability Kit (Invitrogen, 
Carlsbad, CA) following manufacturer’s instructions. The 
fluorescence signals were measured using a SpectraMax M5 
fluorescence microplate reader (Molecular Devices).
statistical analysis
Experiments were conducted in triplicate and repeated three 
times unless otherwise noted. Data were collected, and the 
significant differences were assessed with the probability 
associated with one-tailed Student’s t-tests. Statistical analyses 
were performed using Microsoft Excel (Redmond, WA).
Results and discussion
Material characterization
TEM images of selenium nanoparticles showed that the 
particles were spherical and approximately 40–60 nm in 
diameter (Figure 1). Further investigation of the size distribu-
tion of the selenium nanoparticles by DLS revealed that most 
of the particles had hydrodynamic diameters of around 
100 nm (Figure 2). The sizes observed by DLS were larger 
than those determined by TEM images because BSA mol-
ecules bound to the surface of the selenium nanoparticles 
created a layer that made the particles appear larger.12,13 The 
size-distribution profile demonstrated that the synthesis 
method yielded selenium nanoparticles of a narrow size range 
stable in water. Nanoscale sizes of the synthesized selenium 
nanoparticles promoted a desirable large surface area impor-
tant for increasing interactions with bacteria.
Bacterial assays
When the selenium nanoparticles were mixed with the bacte-
rial solution, the growth of bacteria was inhibited after 
3 hours (compared with the control, 0 µg/mL). The inhibi-
tory effects continued after 4 and 5 hours (Figures 3 and 4). 
The growth profile of bacteria in the presence of selenium 
nanoparticles is presented more clearly in  Figure 4 (with the 
control not plotted). Figure 4 clearly shows a slow, inhibited 
growth profile of bacteria in the presence of selenium nano-
particles. Bacterial growth was inhibited approximately 
20 times (compared with controls) after 3 hours, 50 times 
after 4 hours, and 60 times after 5 hours (Figures 3 and 4).
Live/dead assays were further conducted to determine 
the percentage of live bacteria in each bacterial solution. 
Results showed that at all the concentrations of selenium 
nanoparticles tested and all the time points tested (ie, 3, 4, 
and 5 hours), the percentage of live bacteria in the solution 
having selenium nanoparticles was significantly smaller than 
that in the solution without selenium nanoparticles (ie, con-
trols) (Figure 5). More than 90% of bacteria in the control 
were alive, while only 60% of bacteria were alive in the 
selenium nanoparticle-treated experiments. No significant 
difference in the percentages of live cells was observed 
100 nm
Figure 1 Transmission electron microscopy image of selenium nanoparticles 
stabilized in bovine serum albumin and dispersed in water.
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between the three tested concentrations of selenium 
 nanoparticles. There was also no significant difference in the 
percentage of live cells between the tested time points within 
each concentration of selenium nanoparticles. These live/
dead results indicated that selenium nanoparticles actually 
killed the bacteria rather than inhibiting growth. The selenium 
nanoparticles also continuously killed the bacteria so that 
although the total number of bacteria increased slightly (or 
did not increase during the time period tested), the percentage 
of live cells remained unchanged (Figures 4 and 5).
Discussion
Nanoparticles have been increasingly studied for a wide range 
of medical applications. The advantages of nanoparticles 
include their high surface-to-volume ratios and their nano-
scale sizes. The high surface areas of nanoparticles allow for 
more active sites for interacting with biological entities such 
as cells. The higher surface areas of nanoparticles compared 
with conventional micron-size particles also offer more sites 
for functionalization with other bioactive molecules, such as 
anticancer and antibacterial drug molecules. The nanoscale 
sizes of nanoparticles provide valuable properties that are 
not available in micron particles. For example, nanoparticles 
(with or without drugs attached) of sizes between 10 and 
100 nm can penetrate tissues with tumors and can kill cancer-
ous cells while not affecting healthy cells. This effect, called 
“enhanced permeation and retention,” is attributed to the fact 
that the blood vessels in tissues with tumors have pore sizes 
1
10
B
ac
te
ri
a 
d
en
si
ty
 (
ce
lls
/m
L
)
100
1,000
10,000
100,000
1,000,000
3 hours
4 hours
5 hours
10,000,000
100,000,000
0 µg/mL 7.8 µg/mL 15.5 µg/mL 31 µg/mL
*
* *
Figure 3 Inhibited growth of Staphylococcus aureus in the presence of selenium nanoparticles at all three selenium nanoparticle concentrations: 7.8, 15.5, and 31 µg/mL at all 
tested time points (3, 4, and 5 hours). 
Notes: Data: mean ± standard deviation, n = 3. Bacteria densities in all treated groups (ie, all concentrations of selenium nanoparticles) are significantly lower (*P , 0.01) 
than the control group (0 µg/mL).
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Figure 2 hydrodynamic diameters of the synthesized selenium nanoparticles stabilized in bovine serum albumin and dispersed in deionized water. 
Note: Data: mean ± standard deviation, n = 1.
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ranging from 100 to 800 nm, while the vessels in healthy 
tissues have much smaller pore sizes, from 2 to 6 nm.14
The same advantages can be used for inhibiting bacteria 
functions. Using nanoparticles to impede bacterial growth is 
an increasingly attractive approach to prevent and treat 
infections. Thanks to the advancement of nanotechnology, a 
wide range of nanoparticles (such as iron oxide nanoparticles, 
quantum dots, and gold nanoparticles) have been created. 
However, few studies have reported that nanoparticles can 
effectively kill bacteria, in particular S. aureus. Some 
researchers have reported the synthesis of selenium nanopar-
ticles and their biological effects toward mammalian cells 
in vitro.15,16 Others reported inhibitory effects of selenium 
compounds (in the form of coatings) on the growth of some 
types of bacteria.17 However, the influence of selenium nano-
particles on bacteria growth remains largely unexplored.
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Figure 4 Growth profiles of bacteria in the presence of selenium nanoparticles. 
Notes: Data = mean ± standard deviation, n = 3; *P , 0.05 compared with 3 hours (compared with the same selenium nanoparticles concentration group); **P , 0.05 
compared with 4 hours (compared with the same selenium nanoparticles concentration group). There was no significant difference in bacterial densities between different 
selenium nanoparticle concentrations at each time point tested. (Bacteria densities for control groups are 4,083,480, 11,662,534, and 15,315,887 cells/mL at 3, 4, and 5 hours, 
respectively.)
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Figure 5 Decreased percentages of live bacteria in the presence of selenium nanoparticles. 
Notes: Data = mean ± standard deviation, n = 3; *P , 0.001 compared with all selenium-treated groups at respective time points.
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This study, for the first time, showed that the novel 
 selenium nanoparticles created here by a simple colloidal 
synthesis method, strongly inhibited the growth of S. aureus 
by up to 60 times compared with no treatment. This inhibi-
tory effect of selenium nanoparticles on S. aureus at early 
time points (up to 5 hours) may prevent S. aureus from form-
ing biofilms. In addition, results from live/dead assays 
implied that the selenium nanoparticles killed approximately 
40% of S. aureus after 3, 4, and 5 hours. More in depth and 
longer-term studies which include sodium selenite as a posi-
tive control as well as silver nanoparticles for comparisons 
should be implemented to understand the working mecha-
nisms of such antibacterial selenium properties to further 
develop these promising antibacterial nanoparticles.
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